BNP Paribas Arbitrage SA increased its holdings in shares of Celcuity Inc (NASDAQ:CELC) by 13,655.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,238 shares of the company’s stock after acquiring an additional 1,229 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Celcuity were worth $27,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Strs Ohio boosted its stake in shares of Celcuity by 112.5% in the 4th quarter. Strs Ohio now owns 1,700 shares of the company’s stock valued at $40,000 after purchasing an additional 900 shares in the last quarter. Kessler Investment Group LLC boosted its position in Celcuity by 46.3% during the 1st quarter. Kessler Investment Group LLC now owns 7,017 shares of the company’s stock worth $154,000 after buying an additional 2,222 shares during the period. Bank of New York Mellon Corp boosted its position in Celcuity by 32.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 15,483 shares of the company’s stock worth $445,000 after buying an additional 3,761 shares during the period. JNBA Financial Advisors acquired a new stake in Celcuity during the 4th quarter worth approximately $498,000. Finally, Geode Capital Management LLC boosted its position in Celcuity by 9.1% during the 4th quarter. Geode Capital Management LLC now owns 35,035 shares of the company’s stock worth $840,000 after buying an additional 2,930 shares during the period. 22.05% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on CELC. Zacks Investment Research upgraded shares of Celcuity from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Monday, May 13th. HC Wainwright set a $36.00 price target on shares of Celcuity and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Finally, ValuEngine upgraded shares of Celcuity from a “hold” rating to a “buy” rating in a research report on Friday, March 15th.
Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.04. On average, equities research analysts predict that Celcuity Inc will post -0.81 earnings per share for the current year.
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.